Ascletis announced that the global Phase III clinical program for the once-daily oral administration of the small molecule GLP-1 receptor agonist ASC30 for chronic weight management has completed the first patient administration.

Ascletis announced that the global Phase III clinical program for the once-daily oral administration of the small molecule GLP-1 receptor agonist ASC30 for chronic weight management has completed the first patient administration.